Press Releases

Seattle, WA - Feb 23, 2012

Benaroya Research Institute Welcomes Four New Board Members

Benaroya Research Institute at Virginia Mason (BRI) announced four new members to its Board of Directors. Joining the board are: Edward Drosdick, former chair of the State of Washington Securities Advisory Commission; Stuart Klorfine, grants director of the Klorfine Foundation; Joyce Lammert, MD, PhD, chief of the Department of Medicine at Virginia Mason Medical Center; and Jessica Muffett, founder of YachtWorld.

Edward Drosdick has more than 40 years of experience as an auditor and business advisor in the areas of securities, mergers and acquisitions, technology and the life sciences industry.  He is a retired partner from Moss Adams LLP. He has served on the boards of The Boys and Girls Club of South Seattle and The Make-a-Wish Foundation of the Northwest. He was appointed to the State of Washington Securities Advisory Committee and served as chair of the Commission until its end in 2009.

Stuart Klorfine is a conservation biologist, now serving as the grants director of the Klorfine Foundation based in Philadelphia. He currently serves on the board of the Glacier National Park Fund in Columbia Falls, Mont., and is involved in a variety of environmental projects in the Pacific Northwest.

Joyce Lammert, MD, PhD, is section head of Asthma, Allergy and Immunology and Chief of Medicine at Virginia Mason Medical Center.  She is a clinical associate professor at the University of Washington and has published research on rheumatologic diseases.

Jessica Muffett founded the website YachtWorld.com, the world’s largest Internet yacht brokerage and is now publisher emeritus. She is the founder of the YachtWorld Foundation. She served on the board of the Northwest Marine Trade Association and the board of the Juvenile Diabetes Research Foundation, Northwest Chapter.

Blog Main Image - BRI Building Rear

About Benaroya Research Institute

Benaroya Research Institute (BRI) is a world leader in human immune system research. BRI works to advance the science that will predict, prevent, reverse and cure immune system diseases like allergies, asthma, cancer, COVID-19 and autoimmune diseases. BRI accelerates discovery through laboratory breakthroughs in immunology that are then translated to clinical therapies. We believe that a breakthrough in one immune system disease can lead to progress against them all, and work tirelessly toward our vision of a healthy immune system for everyone. BRI is a world-renowned independent nonprofit research institute affiliated with Virginia Mason Franciscan Health and based in Seattle.

To learn more, visit benaroyaresearch.org and connect with us on Facebook, Instagram, Threads, LinkedIn, X and YouTube.